Evidence map›Paper›PMID 35304631›Full record

ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2022

Impact of the treatment of chronic myeloid leukaemia by tyrosine-kinase inhibitors on sick leaves refund: a nationwide cohort study.

Cécile Conte, Flora Vayr, Marie-Christelle Pajiep, Fabien Despas, Françoise Huguet, Maryse Lapeyre Mestre, Martin Gauthier, Fabrice Herin

Abstract read
PubMed Publisher
In one paragraph

Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Cécile ConteClinical Pharmacology Department, Toulouse University Hospital, Toulouse, France.
Flora VayrClinical Investigation Center (CIC 1436, INSERM and Toulouse University Hospital, Toulouse, France.
Marie-Christelle PajiepClinical Pharmacology Department, Toulouse University Hospital, Toulouse, France.
Fabien DespasClinical Pharmacology Department, Toulouse University Hospital, Toulouse, France.
Françoise HuguetDepartment of Haematology, Toulouse University Hospital, IUCT-O, Toulouse, France.
Maryse Lapeyre MestreClinical Pharmacology Department, Toulouse University Hospital, Toulouse, France.
Martin GauthierDepartment of Internal Medicine and Haematology, CH Cahors, Cahors, France. martin.gauthier@hotmail.fr.ORCID http://orcid.org/0000-0001-5338-2071
Fabrice HerinClinical Investigation Center (CIC 1436, INSERM and Toulouse University Hospital, Toulouse, France.
Inserm · FRGroupe Cahors (France) · FRUniversité Fédérale de Toulouse Midi-Pyrénées · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe advent of chronic myeloid leukaemia (CML) tyrosine-kinase inhibitors (TKI) has led to new paradigms including occupational rehabilitation.

objectivesThis study aimed to characterize the impact of CML treatment on sick leaves within the 2 years following diagnosis in working-age patients.

methodsA cohort of all 18-60-year-old newly diagnosed CML patients initiating a TKI between January 1

resultsAmong 646 18-60-year-old patients, 268 were prescribed at least one sick leave in the study period, with 176 (27.2%) having their first sick leave prescribed after TKI initiation. The median number of sick days over the 2-years period was 115 per patient (interquartile range 25.5-384.5). In the nested case-control study (176 cases and 176 matched controls), sick leaves were more likely observed with second generation TKI (OR 4.11 [1.80-9.38]), whereas they were less likely observed in case if social deprivation (OR 0.07 [0.02-0.28].

conclusionMore than 25% of working-age CML patients had at least one sick leave within 2 years of TKI initiation, with a higher impact of second generation TKI, and with a median duration of 115 days.

Indexed as

Leukemia, Myelogenous, Chronic, BCR-ABL PositiveSick LeaveAdolescentAdultCase-Control StudiesCohort StudiesHumansMiddle AgedProtein Kinase InhibitorsTyrosineYoung AdultProtein Kinase InhibitorsTyrosineMyeloproliferative neoplasmsQuality of lifeSocioeconomics and ethicsSupportive care

Identifiers

PMID35304631
OpenAlexW4220948375

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.